Literature DB >> 21820763

[The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up].

Paz Sobrino-Vegas1, Félix Gutiérrez, Juan Berenguer, Pablo Labarga, Federico García, Belén Alejos-Ferreras, M Angeles Muñoz, Santiago Moreno, Julia del Amo.   

Abstract

INTRODUCTION: This article describes the development of the Cohort of the Spanish Research Network (CoRIS), its methodological and organizational aspects, the demographic and clinical characteristics of the subjects enrolled and quantifies the losses to follow-up and associated factors.
METHODS: Multicentre cohort of HIV-positive naïve subjects recruited in 28 sites of Spain from 2004-onwards. Missing and inconsistent data were submitted to internal quality controls and the datasets were externally audited. Multiple logistic regression models were used.
RESULTS: As of October 2009, 5,514 subjects had been recruited, representing 11,708 person-years with a median follow-up time of 1.81 years. Most are men (78.8%), infected by sexual transmission (46.1% men who have sex with men and 35.2% heterosexual persons) and Spanish (69.7%). During follow-up 64.5% have started Antiretroviral Therapy (ART) and 201 deaths have occurred. New HIV diagnoses accounted for 80.7% of the sample. Some 52% of subjects had at least one baseline sample in the BioBank while naïve to ART. Losses to follow-up (18.9%) were more frequent in younger people, in injecting drug users, in persons of non-Spanish origin, in persons with primary or lower educational level, and in those with a CD4 count over 350 cells/mm(3) at time of recruitment.
CONCLUSIONS: The implementation of CoRIS has been successful; the cohort has wide representation at national level, is actively recruiting new members and blood samples, and has excellent data quality. Losses to follow-up are of similar magnitude to other cohort studies, as are the factors associated with them.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820763     DOI: 10.1016/j.eimc.2011.06.002

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  29 in total

1.  Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

Authors:  Margaret T May; Robert S Hogg; Amy C Justice; Bryan E Shepherd; Dominique Costagliola; Bruno Ledergerber; Rodolphe Thiébaut; M John Gill; Ole Kirk; Ard van Sighem; Michael S Saag; Gemma Navarro; Paz Sobrino-Vegas; Fiona Lampe; Suzanne Ingle; Jodie L Guest; Heidi M Crane; Antonella D'Arminio Monforte; Jörg J Vehreschild; Jonathan A C Sterne
Journal:  Int J Epidemiol       Date:  2012-11-12       Impact factor: 7.196

2.  Genetic polymorphisms of Trim5a are associated with disease progression in acutely and chronically HIV-infected patients.

Authors:  Xin Sun; Wei Li; Wenzhen Liu; Rui Wang; Qunhui Li; Hao Wu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort.

Authors:  Montserrat Torres; Cristina González; Jorge del Romero; Pompeyo Viciana; Antonio Ocampo; Patricia Rodríguez-Fortúnez; Mar Masiá; José Ramón Blanco; Joaquín Portilla; Carmen Rodríguez; Beatriz Hernández-Novoa; Julia del Amo; Marta Ortiz
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

4.  Imputation of the Date of HIV Seroconversion in a Cohort of Seroprevalent Subjects: Implications for Analysis of Late HIV Diagnosis.

Authors:  Paz Sobrino-Vegas; Santiago Pérez-Hoyos; Ronald Geskus; Belén Padilla; Ferrán Segura; Rafael Rubio; Jorge Del Romero; Jesus Santos; Santiago Moreno; Julia Del Amo
Journal:  AIDS Res Treat       Date:  2011-10-15

5.  Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors.

Authors:  Ronald B Geskus; Cristina González; Montserrat Torres; Jorge Del Romero; Pompeyo Viciana; Mar Masiá; José R Blanco; Mauricio Iribarren; Silvia De Sanjosé; Beatriz Hernández-Novoa; Marta Ortiz; Julia Del Amo
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

6.  Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations.

Authors:  Susana Monge; Vicente Guillot; Marta Alvarez; Natalia Chueca; Natalia Stella; Alejandro Peña; Rafael Delgado; Juan Córdoba; Antonio Aguilera; Carmen Vidal; Federico García
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

7.  Reproductive desire in women with HIV infection in Spain, associated factors and motivations: a mixed-method study.

Authors:  Victoria Hernando; Belén Alejos; Débora Álvarez; Marta Montero; M Jesús Pérez-Elías; Jose Ramón Blanco; Mar Masiá; Jorge Del Romero; Ignacio de los Santos; Isabel Rio; Alicia Llácer
Journal:  BMC Pregnancy Childbirth       Date:  2014-06-05       Impact factor: 3.007

Review 8.  Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.

Authors:  Juan Berenguer; Cristina Díez; María Martín-Vicente; Rafael Micán; María J Pérez-Elías; Lucio J García-Fraile; Francisco Vidal; Inés Suárez-García; Daniel Podzamczer; Jorge Del Romero; Federico Pulido; José A Iribarren; Félix Gutiérrez; Eva Poveda; Carlos Galera; Rebeca Izquierdo; Víctor Asensi; Joaquín Portilla; Juan C López; José R Arribas; Santiago Moreno; Juan González-García; Salvador Resino; Inmaculada Jarrín
Journal:  Clin Microbiol Infect       Date:  2021-06-26       Impact factor: 8.067

9.  All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010.

Authors:  Victoria Hernando; Belen Alejos; Susana Monge; Juan Berenguer; Lourdes Anta; David Vinuesa; Rosario Palacios; Roberto Muga; Santiago Moreno; Inma Jarrin
Journal:  BMC Infect Dis       Date:  2013-08-20       Impact factor: 3.090

10.  Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.

Authors:  Inés Suárez-García; Belén Alejos; Marta Ruiz-Algueró; Cristina García Yubero; Cristina Moreno; Enrique Bernal; Laura Pérez-Is; Zuriñe Zubero; Miguel Alberto de Zárraga Fernández; Gloria Samperiz Abad; Inma Jarrín
Journal:  J Int AIDS Soc       Date:  2021-07       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.